Codexis (CDXS) Q2 2026 earnings review
Product Mix Shift Rescues Topline as Cash Raise Secures the Future
Codexis delivered a quarter of stable total revenue ($14.9M, -3% YoY) that masked a dramatic underlying pivot. Legacy R&D service revenue collapsed, but high-margin product revenue surged 79% YoY to $13.2M, driven by new commercial launches. This favorable mix pushed gross margins to 73% and, combined with structural cost cuts, narrowed the operating loss. More importantly, management eliminated the biggest overhang on the stock by raising $25M in July, extending the cash runway through 2028 and fully funding the critical ECO Synthesis GMP facility buildout.
🐂 Bull Case
Product gross margin expanded to 73% (vs 72% a year ago and 55% in 25Q1), proving the legacy biocatalysis business can generate high-quality cash flow to support the ECO Synthesis transition.
The $25M July equity raise pushes the cash runway from 2027 to the end of 2028. Management now has the capital to complete the Hayward GMP facility without near-term dilution threats.
🐻 Bear Case
With only $30.1M in H1 revenue, Codexis needs roughly $44M in H2 to hit the midpoint of its $74M full-year guidance—requiring flawless execution on commercial milestones.
R&D revenue fell 79% YoY to $1.7M. The legacy small-molecule service business is winding down fast, and new ECO Synthesis service contracts aren't yet bridging the gap.
⚖️ Verdict: ⚪
Neutral to Bullish. The structural mix shift toward high-margin product sales is a major positive. While the steep H2 guidance ramp introduces near-term execution risk, the extended cash runway through 2028 buys management the time needed to commercialize the ECO Synthesis platform.
Key Themes
Product Revenue Surges as New Customer Launches Hit
Product revenue jumped 79% YoY to $13.2M. Management explicitly attributed this to the approval and launch of new, higher-margin products by customers (likely referencing the recent Merck islatravir approval mentioned in previous quarters). This effectively offset the collapse in R&D revenue and proves the 'cash-cow' utility of the legacy biocatalysis portfolio.
Stereoisomer Control Validated at TIDES
Codexis presented new data confirming its ECO Synthesis platform exerts enzyme-driven stereoisomer control of siRNA and can initiate synthesis from a single nucleotide. This is a critical technological differentiator against solid-phase synthesis, allowing for precise engineering of RNA structures to improve drug potency and reduce side effects—a massive selling point for innovators.
Capital Raise De-risks GMP Facility Timeline
The company raised $25M in net proceeds in July, boosting pro-forma cash to ~$80M. This successfully extends the cash runway to the end of 2028 (up from 2027 previously). This funding specifically covers the retrofit of the Hayward ECO GMP Manufacturing Center, scheduled to begin in H2 2026, without the need for distressed financing.
R&D Services Collapse Contradicts "Strong" Narrative
While management highlighted 'strong financial results', R&D revenue collapsed by 79% YoY (from $7.9M to $1.7M). This sharp deceleration highlights that the legacy small-molecule service business is drying up faster than the new ECO Synthesis partnerships are scaling, leaving the company heavily reliant on product sales lumpiness.
Macro Bottleneck: siRNA Manufacturing Capacity
The entire strategic pivot to the ECO Synthesis GMP Center relies on an impending industry bottleneck. As RNAi therapeutics shift from rare diseases to large-population cardiovascular indications, the industry requires a 10x-50x increase in production capacity by 2030. Codexis is racing to get its GMP facility online by 2027 to capture this macro supply-demand imbalance.
Other KPIs
Total operating expenses decelerated, dropping 13% YoY from $26.1M in 25Q2. The reductions were driven by lower headcount from prior restructuring and reduced outside services, showing management's commitment to protecting cash during the ECO Synthesis scale-up phase.
Accelerating slightly from 72% in 25Q2 and 71% in 26Q1. The margin expansion is structural, driven by a deliberate shift away from lower-margin legacy products toward newly launched, highly profitable commercial enzymes.
Guidance
Reiterated. Implies a sharp acceleration in the second half. With H1 revenue at $30.1M, Codexis must generate ~$44M in H2 to meet the midpoint. This indicates high reliance on milestone payments, lump-sum technology transfers, or large batch commercial orders in Q3/Q4.
Reiterated. Since 26H1 product gross margins operated at ~72%, guidance implies slight margin deceleration in H2, likely due to product mix variations or upfront costs associated with scaling early-phase ECO Synthesis contracts.
Accelerating. Extended by a full year from previous 'End of 2027' guidance, entirely due to the $25M capital raise completed in July 2026.
Key Questions
H2 Revenue Bridge
With a requirement of ~$44M in H2 to meet the midpoint of your guidance, how much of this is tied to predictable commercial product reorders versus uncontracted milestones or new licensing deals?
R&D Revenue Floor
R&D revenue dropped below $2M this quarter. Have we reached the bottom of the legacy service wind-down, and when should we expect ECO Synthesis feasibility studies to start driving meaningful R&D revenue growth?
CDMO Strategic Partnership Update
Guidance explicitly calls for an additional strategic CDMO partnership by the end of 2026. What specific capabilities are you looking for in this partner that your current network (Nitto, Axolabs) does not provide?
FDA Emerging Technologies Engagement
With the FDA meeting planned for Q4 regarding ECO Synthesis product comparability and stereoisomer control, what specific feedback are you seeking to de-risk the regulatory pathway for your innovator clients?